Autologous hematopoietic stem cell transplantation for non-AL amyloidosis monoclonal gammopathy of renal significance
This study confirmed that ASCT was an effective and safe treatment for patients with non-AL amyloidosis MGRS, thereby offering long-term hematological remission and survival benefits.
Authors
- Wencui Chen (ORCID: https://orcid.org/0000-0001-6706-5237)
- Xianghua Huang (ORCID: https://orcid.org/0000-0002-0243-9426)
- Mengnan Liu (ORCID: https://orcid.org/0000-0002-2740-4182)
- Jinzhou Guo (ORCID: https://orcid.org/0000-0001-7530-4576)
- Liang Zhao (ORCID: https://orcid.org/0009-0002-7034-4231)
- Xiaomei Wu (ORCID: https://orcid.org/0000-0002-8406-0005)
- Weiwei Xu
Institutions
- Nanjing General Hospital of Nanjing Military Command (CN)
- National Clinical Research (US)
- Nanjing University (CN)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1093/ndt/gfaf036
- Citations
- 1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.81